A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease

International Journal of Cancer

Volumn 125, Issue 4, 2009, Pages 879-886

  Brinkrolf, Peter ^a   Landmeier, Silke ^a   Altvater, Bianca ^a   Chen, Christiane ^a   Pscherer, Sibylle ^a   Rosemann, Annegret ^a   Ranft, Andreas ^a   Dirksen, Uta ^a   Juergens, Heribert ^a   Rossig, Claudia ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Bone marrow; Ewing sarcoma; Regulatory T cells; Tumor immunology

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW CELL; BONE METASTASIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EWING SARCOMA; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MALE; MEMORY T LYMPHOCYTE; MESENCHYME CELL; MICROSCOPY; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK FACTOR;

ADOLESCENT; ADULT; ANTIGENS, CD4; BONE MARROW; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PROGNOSIS; SARCOMA, EWING'S; SURVIVAL RATE; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 67650091383     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24461     Document Type: Article

References (63)

1. Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, Frohlich B, Winkelmann W, Zoubek A, Jurgens H. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European intergroup cooperative Ewing sarcoma Studies. Ann Oncol 1998;9:275-81.
2. Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Kohler G, Poremba C, Zoubek A, Ladenstein R, et al. Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment - cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008;26:4385-93.
3. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008;14:4850-58.
4. De Angulo G, Hernandez M, Morales-Arias J, Herzog CE, Anderson P, Wolff J, Kleinerman ES. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol 2007;29:48-52.
5. Mechtersheimer G, Barth T, Ludwig R, Staudter M, Moller P. Differential expression of leukocyte differentiation antigens in small round blue cell sarcomas. Cancer 1993;71:237-48.
6. Berghuis D, de Hooge AS, Santos SJ, Horst D, Wiertz EJ, van Eggermond MC, van den Elsen PJ, Taminiau AH, Ottaviano L, Schaefer KL, Dirksen U, Hooijberg E, et al. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 2009 Feb 2 [Epub ahead of print].
7. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-9.
8. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A, Stamenkovic I. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005;65:11459-68.
9. Castillero-Trejo Y, Eliazer S, Xiang LL, Richardson JA, Ilaria RL. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent. Ewing sarcoma-like tumors. Cancer Res 2005;65:8698-705.
10. Avigad S, Cohen IJ, Zilberstein J, Liberzon E, Goshen Y, Ash S, Meller I, Kollender Y, Issakov J, Zaizov R, Yaniv I. The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer 2004;100:1053-8.
11. Kovar H. Ewing tumor biology: perspectives for innovative treatment approaches. Adv Exp Med Biol 2003;532:27-37.
12. Phillips RF, Higinbotham NL. Curability of Ewings endothelioma of bone in children. J Pediatrics 1967;70:391-7.
13. Tripp RA, Topham DJ, Watson SR, Doherty PC. Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. J Immunol 1997;158:3716-20.
14. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, Hammerling GJ, Kyewski B, Hamann A, Umansky V, Schirrmacher V. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003;9:1151-7.
15. Kulkosky J, Bouhamdan M, Geist A, Nunnari G, Phinney DG, Pomerantz RJ. Pathogenesis of HIV-1 infection within bone marrow cells. Leuk Lymph 2000;37:497-515.
16. Letsch A, Knoedler M, Na IK, Kern F, Asemissen AM, Keilholz U, Loesch M, Thiel E, Volk HD, Scheibenbogen C. CMV-specific central memory T cells reside in bone marrow. Eur J Immunol 2007;37:3063-8.
17. Palendira U, Chinn R, Raza W, Piper K, Pratt G, Machado L, Bell A, Khan N, Hislop AD, Steyn R, Rickinson AB, Buckley CD, et al. Selective accumulation of virus-specific CD8(+) T cells with unique homing phenotype within the human bone marrow. Blood 2008;112:3293-302.
18. Khazaie K, Prifti S, Beckhove P, Griesbach A, Russell S, Collins M, Schirrmacher V. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA 1994;91:7430-4.
19. Feuerer M, Rocha M, Bai L, Umansky V, Solomayer EF, Bastert G, Diel IJ, Schirrmacher V. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 2001;92:96-105.
20. Muller-Berghaus J, Ehlert K, Ugurel S, Umansky V, Bucur M, Schirrmacher V, Beckhove P, Schadendorf D. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. Cancer Res 2006;66:5997-6001.
21. Schmitz-Winnenthal FH, Volk C, Z'Graggen K, Galindo L, Nummer D, Ziouta Y, Bucur M, Weitz J, Schirrmacher V, Buchler MW, Beckhove P. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005;65:10079-87.
22. Sommerfeldt N, Schutz F, Sohn C, Forster J, Schirrmacher V, Beckhove P. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006;66:8258-65.
23. Montagna D, Maccario R, Locatelli F, Montini E, Pagani S, Bonetti F, Daudt L, Turin I, Lisini D, Garavaglia C, Dellabona P, Casorati G. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood 2006;108:3843-50.
24. Fisch P, Malkovsky M, Kovats S, Sturm E, Braakman E, Klein BS, Voss SD, Morrissey LW, DeMars R, Welch WJ, Bolhuis RLH, Sondel P. Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science 1990;250:1269-73.
25. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8.
26. Grau R, Lang KS, Wernet D, Lang P, Niethammer D, Pusch CM, Handgretinger R. Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hernatopoietic stem cells in healthy individuals. Exp Mol Pathol 2004;76:90-8.
27. Zou LH, Barnett B, Safah H, LaRussa VF, Evdemon-Hogan M, Mottram P, Wei SN, David O, Curiel TJ, Zou WP. Bone marrow is a reservoir for CD4(+)CD25(+) regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004;64:8451-5.
28. Shevach EM. Regulatory T cells in autoimmmunity. Ann Rev Immunol 2000;18:423-49.
29. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
30. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755-62.
31. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L. Foxp3 expressing CD4(+) CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
32. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
33. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, Classen S, Schultze JL. In vivo peripheral expansion of naive CD4(+)CD25(high) FoxP3(+) regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940-9.
34. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93.
35. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, et al. Intraepithelial CD8(+) tumor-infiltrating lymphocytes and a high CD8(+)/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-43.
36. Salzer-Kuntschik M, Brand G, Delling G. Determination of degrees of morphological regression after chemotherapy of malignant bone-tumors. Pathologe 1983;4:135-41.
37. Zhang X, Dong H, Lin W, Voss S, Hinkley L, Westergren M, Tian G, Berry D, Lewellen D, Vile RG, Chen L, Farber DL, Strome SE. Human bone marrow: a reservoir for "enhanced effector memory." CD8+ T cells with potent recall function. J Immunol 2006;177:6730-7.
38. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing's sarcoma study group. J Clin Oncol 2000;18:3108-14.
39. Comans-Bitter WM, deGroot R, van den Beemd R, Neijens HJ, Hop WCJ, Groeneveld K, Hooijkaas H, van Dongen JJM. Immunophenotyping of blood lymphocytes in childhood - reference values for lymphocyte subpopulations. J Pediatrics 1997;130:388-93.
40. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25(+)CD4(+) T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-18.
41. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
42. Javia LR, Rosenberg SA. CD4(+)CD25(+) suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 2003;26:85-93.
43. Woo EY, Yeh H, Chu CS, Schleinger K, Carroll RG, Riley JL, Kaiser LR, June CH. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
44. Rosen G, Caparros B, Mosende C, Mccormick B, Huvos AG, Marcove RC. Curability of Ewings sarcoma and considerations for future therapeutic trials. Cancer 1978;41:888-99.
45. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999;91:1113-24.
46. Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, Ho A, Schirrmacher V, Goldschmidt H, Beckhove P. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005;105:2132-4.
47. Letsch A, Keilholz U, Assfalg G, Mailander V, Thiel E, Scheibenbogen C. Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. Cancer Res 2003;63:5582-6.
48. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452-8.
49. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous pre-malignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003;198:1753-7.
50. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA. Local and systemic induction of CD4(+)CD25(+) regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359-70.
51. de Hooge AS, Berghuis D, Santos SJ, Mooiman E, Romeo S, Kummer JA, Egeler RM, van Tol MJ, Melief CJ, Hogendoorn PC, Lankester AC. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res 2007;13:206-14.
52. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8(+) T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305.
53. Mazo IB, Honczarenko M, Leung H, Cavanagh LL, Bonasio R, Weninger W, Engelke K, Xia L, McEver RP, Koni PA, Silberstein LE, von Andrian UH. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 2005;22:259-70.
54. Kosmidis S, Baka M, Bouhoutsou D, Doganis D, Kallergi C, Douladiris N, Pourtsidis A, Varvoutsi M, Saxoni-Papageorgiou F, Vasilatou-Kosmidis H. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. Pediatr Blood Cancer 2008;50:528-32.
55. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL, Gress RE. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-8.
56. Mazur B, Szczepanski T, Karpe J, Sonta-Jakimczyk D, Bubala H, Torbus M. Decreased numbers of CD4+ T lymphocytes in peripheral blood after treatment of childhood acute lymphoblastic leukemia. Leuk Res 2006;30:33-6.
57. Petrini B, Wasserman J, Blomgren H, Rotstein S. Changes of blood T cell subsets in patients receiving postoperative adjuvant chemotherapy for breast cancer. Eur J Cancer Clin Oncol 1984;20:1485-7.
58. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002;188:9-21.
59. Duval M, Yotnda P, Bensussan A, Oudhiri N, Guidal C, Rohrlich P, Boumsell L, Grandchamp B, Vilmer E. Potential antileukemic effect of gamma-delta T-Cells in acute lymphoblastic-leukemia. Leukemia 1995;9:863-8.
60. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PC, Egeler RM, van Tol MJ, Schilham MW, Lankester AC. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008;45:3917-25.
61. Zimmer J, Andres E, Hentges F. NK cells and Treg cells: a fascinating dance cheek to cheek. Eur J Immunol 2008;38:2942-5.
62. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
63. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008;112:610-8.